Edition:
United States

XBiotech Inc (XBIT.OQ)

XBIT.OQ on NASDAQ Stock Exchange Global Select Market

4.79USD
23 Feb 2018
Change (% chg)

$0.03 (+0.63%)
Prev Close
$4.76
Open
$4.76
Day's High
$4.83
Day's Low
$4.75
Volume
9,467
Avg. Vol
37,909
52-wk High
$20.18
52-wk Low
$2.80

Chart for

About

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $169.75
Shares Outstanding(Mil.): 35.44
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-XBIOTECH ‍ENROLLS FIRST PATIENT IN STUDY EVALUATING MABP1 IN WITH ONIVYDE

* ‍ENROLS FIRST PATIENT IN STUDY EVALUATING MABP1 IN COMBINATION WITH ONIVYDE & 5-FLUOROURACIL/FOLINIC ACID FOR TREATMENT OF PANCREATIC CANCER​ Source text for Eikon: Further company coverage:

Oct 18 2017

BRIEF-XBiotech announces agreement with Cedars-Sinai Medical Center to evaluate MABP1 combination for the treatment of pancreatic cancer

* Xbiotech announces agreement with Cedars-Sinai Medical Center to evaluate MABP1 in combination with Onivyde and 5-fluorouracil/folinic acid for the treatment of pancreatic cancer Source text for Eikon: Further company coverage:

Sep 20 2017

BRIEF-XBiotech - European Medicines Agency maintains its May 18, 2017 opinion

* XBiotech - on Sept 14, although there were advancements in certain areas of application European Medicines Agency has maintained its May 18, 2017 opinion

Sep 15 2017

Earnings vs. Estimates